For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval that, according to one of the world’s leading leukemia experts, is showing “significant ...

Michael J. Mauro, MD, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, at Memorial Sloan Kettering Cancer Center, discusses the current understanding of TKI discontinuation ...

CML HealthCare Inc. , a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, is pleased to announce that Canada's largest, automated ...